Program
Insulin Glargine
Also written as “insulin glargine”, “Insulin glargine” and “INSULIN GLARGINE”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Hyperglycemia · Glucose Intolerance, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 1241 open or running | phase 4since Sep 9, 2005 | Sep 30, 2002 | none ahead |
| Novo Nordisk | 280 open or running | phase 4since Sep 12, 2005 | Oct 29, 2004 | none ahead |
| Eli Lilly | 250 open or running | phase 4since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Diabetes Care Center | 20 open or running | no phasesince Apr 3, 2007 | Apr 3, 2007 | none ahead |
| Biodel | 10 open or running | phase 2since Oct 21, 2009 | Oct 21, 2009 | none ahead |
| Geropharm | 10 open or running | no phasesince Sep 23, 2019 | Sep 23, 2019 | none ahead |
| ikfe-cro-gmbh | 10 open or running | phase 4since Dec 5, 2011 | Dec 5, 2011 | none ahead |
| Profil Institut für Stoffwechselforschung | 10 open or running | phase 1since Sep 3, 2009 | Sep 3, 2009 | none ahead |
| Wockhardt | 10 open or running | phase 1since May 12, 2011 | May 12, 2011 | none ahead |
Also a collaborator on its studies: ppd-development-lp, Alkermes and Boehringer Ingelheim.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Sep 14, 2012.
- Dec 5, 2018Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT03767543 · 265 enrolled · Canada
- Jan 7, 20192 phase 3 studies in Diabetes Mellitus, Type 2Sanofi · NCT03798080, NCT03798054
- Aug 29, 2019Phase 4 study in Diabetes Mellitus, Type 1Sanofi · NCT04075513 · 343 enrolled · United States, Brazil, Germany and more
- Sep 23, 2019Geropharm's first study: no phase study in Clamp StudyNew to GeropharmGeropharm · NCT04101383 · 42 enrolled · Russian Federation
- Nov 5, 2019Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT04153981 · 304 enrolled · India
- Jul 10, 2020No phase study in Diabetes Mellitus, Type 1Eli Lilly · NCT04484779 · 67 enrolled · United States
- Apr 27, 2021Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT04864977 · United States
- Jul 19, 2021Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT04980027 · 228 enrolled · India
- Oct 29, 2021Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT05114590 · 124 enrolled · United States
- Jun 7, 2022Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT05413369 · 582 enrolled · China
- Jul 14, 2022Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT05462756 · 730 enrolled · United States, Argentina, Germany and more
- Sep 7, 2022Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT05552859 · 62 enrolled · United States, Czechia, Hungary and more
- Mar 26, 2024Phase 3 study in Diabetes Mellitus, Type 2Novo Nordisk · NCT06340854 · 412 enrolled · United States, Bulgaria, Germany and more
- Oct 31, 2024Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT06671587 · 678 planned · China
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
The newest 60 of 184 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06671587Diabetes Mellitus, Type 2 · China | 4 | Recruiting | Sanofi | Sep 18, 2026 | 678 |
| NCT06340854Diabetes Mellitus, Type 2 · United States, Bulgaria, Germany and more | 3 | Completed | Novo Nordisk | May 8, 2025 | 412 |
| NCT05552859Diabetes Mellitus, Type 2 · United States, Czechia, Hungary and more | 4 | Terminated | Sanofi | Jul 28, 2023 | 62 |
| NCT05462756Diabetes Mellitus, Type 2 · United States, Argentina, Germany and more | 3 | Completed | Eli Lilly | Feb 27, 2024 | 730 |
| NCT05413369Diabetes Mellitus, Type 2 · China | 3 | Completed | Sanofi | Oct 20, 2023 | 582 |
| NCT05114590Diabetes Mellitus, Type 2 · United States | 4 | Completed | Sanofi | Mar 28, 2023 | 124 |
| NCT04980027Diabetes Mellitus, Type 2 · India | 4 | Completed | Sanofi | Dec 23, 2022 | 228 |
| NCT04864977Diabetes Mellitus, Type 2 · United States | 4 | Withdrawn | Eli Lilly | Jun 6, 2022 | 0 |
| NCT04484779Diabetes Mellitus, Type 1 · United States | – | Completed | Eli Lilly | Dec 22, 2020 | 67 |
| NCT04153981Diabetes Mellitus, Type 2 · India | 4 | Completed | Eli Lilly | Jul 30, 2021 | 304 |
| NCT04101383Clamp Study · Russian Federation | – | Completed | Geropharm | Feb 16, 2018 | 42 |
| NCT04075513Diabetes Mellitus, Type 1 · United States, Brazil, Germany and more | 4 | Completed | Sanofi | Sep 16, 2021 | 343 |
| NCT03798080Diabetes Mellitus, Type 2 · China | 3 | Completed | Sanofi | Dec 1, 2020 | 426 |
| NCT03798054Diabetes Mellitus, Type 2 · China, Korea, Republic of, Malaysia and more | 3 | Completed | Sanofi | Mar 1, 2021 | 878 |
| NCT03767543Diabetes Mellitus, Type 2 · Canada | 3 | Completed | Sanofi | Oct 23, 2020 | 265 |
| NCT03760991Diabetes Mellitus, Type 2 · Argentina, Colombia, Egypt and more | 4 | Completed | Sanofi | Sep 23, 2020 | 372 |
| NCT03555305Healthy · China | 1 | Completed | Eli Lilly | Nov 4, 2019 | 58 |
| NCT03529123Diabetes Mellitus, Type 2 · India | 3 | Completed | Sanofi | Nov 25, 2019 | 247 |
| NCT03434119Diabetes Mellitus, Type 2 · United States | 3 | Terminated | Sanofi | Jan 7, 2019 | 241 |
| NCT03406000Diabetes Mellitus, Type 1 · Brazil | 4 | Completed | Sanofi | Feb 4, 2019 | 170 |
| NCT03359837Diabetes Mellitus, Type 2 · China | 4 | Completed | Sanofi | Jun 29, 2020 | 384 |
| NCT03338023Diabetes Mellitus, Type 1 · China | 3 | Completed | Eli Lilly | Mar 5, 2020 | 272 |
| NCT03338010Diabetes Mellitus, Type 2 · China | 3 | Completed | Eli Lilly | Mar 18, 2020 | 536 |
| NCT03260868Diabetes Mellitus, Type 1 · United States, Canada | 4 | Terminated | Sanofi | Nov 22, 2018 | 15 |
| NCT02967237Diabetes Mellitus, Type 2 · France | 4 | Completed | Sanofi | Jul 24, 2017 | 136 |
| NCT02967224Diabetes Mellitus, Type 2 · Brazil, France, Germany and more | 4 | Completed | Sanofi | Oct 16, 2017 | 705 |
| NCT02967211Diabetes Mellitus, Type 2 · Brazil, Finland, France and more | 4 | Completed | Sanofi | Oct 20, 2017 | 609 |
| NCT02955953Healthy · Singapore | 1 | Completed | Eli Lilly | Jan 4, 2017 | 127 |
| NCT02855684Diabetes Mellitus, Type 2 · China, Korea, Republic of, Taiwan | 3 | Completed | Sanofi | Aug 6, 2018 | 604 |
| NCT02836704Diabetes Mellitus, Type 2 · China | 4 | Completed | Sanofi | Apr 26, 2018 | 892 |
| NCT02787551Diabetes Mellitus, Type 2 · United States, Canada, Estonia and more | 3 | Completed | Sanofi | May 25, 2018 | 514 |
| NCT02752828Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Sanofi | Mar 12, 2018 | 521 |
| NCT02752412Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Sanofi | Oct 4, 2018 | 513 |
| NCT02749890Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Sanofi | May 2018 | 321 |
| NCT02738151Diabetes Mellitus, Type 2 · United States, Bulgaria, Croatia and more | 4 | Completed | Sanofi | Aug 15, 2017 | 929 |
| NCT02735044Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more | 3 | Completed | Sanofi | May 31, 2018 | 463 |
| NCT02713477Diabetes Mellitus, Type 2 · Japan | 1 | Completed | Sanofi | Jun 2016 | 20 |
| NCT02688933Diabetes Mellitus, Type 1 · United States, Puerto Rico | 4 | Completed | Sanofi | Jun 19, 2017 | 638 |
| NCT02606357Diabetes Mellitus, Type 2 · Jordan | 4 | Completed | Sanofi | Nov 27, 2017 | 242 |
| NCT02545842Diabetes Mellitus, Type 2 · China | 4 | Completed | Sanofi | Apr 20, 2018 | 947 |
| NCT02451137Diabetes Mellitus, Type 2 · United States, Canada | 4 | Completed | Sanofi | Mar 2, 2018 | 3,304 |
| NCT02401243Diabetes Mellitus, Type 2 · Canada | 3 | Completed | Sanofi | Feb 2016 | 253 |
| NCT02320721Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Sanofi | May 2016 | 1,014 |
| NCT02302716Diabetes Mellitus, Type 2 · United States, India, Korea, Republic of and more | 3 | Completed | Eli Lilly | Jul 2016 | 493 |
| NCT02227212Diabetes Mellitus, Type 2 · Germany | 3 | Completed | Sanofi | Nov 2014 | 40 |
| NCT02201199Diabetes Mellitus, Type 1 · Germany | 1 | Completed | Sanofi | Nov 2014 | 36 |
| NCT02132637Diabetes Mellitus, Type 2 · United States, Germany | 3 | Completed | Eli Lilly | Jul 2015 | 68 |
| NCT02058160Diabetes Mellitus, Type 2 · United States, Australia, Canada and more | 3 | Completed | Sanofi | Jul 2015 | 736 |
| NCT02058147Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more | 3 | Completed | Sanofi | Jun 2015 | 1,170 |
| NCT02034513Diabetes Mellitus · United States, Poland, Puerto Rico | 3 | Completed | Novo Nordisk | Jan 11, 2016 | 501 |
| NCT02030600Diabetes Mellitus · United States, Puerto Rico | 3 | Completed | Novo Nordisk | Dec 4, 2015 | 721 |
| NCT02027753Diabetes Mellitus, Type 2 · Korea, Republic of | 4 | Completed | Sanofi | Apr 2015 | 109 |
| NCT01868529Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jun 2008 | 63 |
| NCT01849289Diabetes Mellitus · United States, Brazil, Canada and more | 3 | Completed | Novo Nordisk | May 15, 2014 | 833 |
| NCT01838083Type1 Diabetes · Germany | 1 | Completed | Sanofi | Aug 2013 | 50 |
| NCT01730014Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jul 2013 | 70 |
| NCT01704417Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Mar 2013 | 40 |
| NCT01688635Healthy · Singapore | 1 | Completed | Eli Lilly | Feb 2013 | 91 |
| NCT01689142Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Sanofi | Nov 2013 | 240 |
| NCT01689129Diabetes Mellitus, Type 1 · Japan | 3 | Completed | Sanofi | Oct 2013 | 243 |
How it is read
Names in the registry
- “insulin glargine”, 38 entries
- “Insulin Glargine”, 27 entries
- “Insulin glargine”, 20 entries
- “INSULIN GLARGINE”, 15 entries
- “LY2963016”, 11 entries
Codes read as this program: HOE901.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 124 studies
- Diabetes Mellitus, Type 1, 44 studies
- Diabetes Mellitus, 14 studies
- Hyperglycemia, 1 study
- Glucose Intolerance, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.